No abstract available.
Arthritis, Psoriatic* ; Humans ; Psoriasis*

No abstract available.
Arthritis, Psoriatic* ; Macrophages* ; Scleroderma, Systemic*

No abstract available.
Arthritis, Psoriatic* ; Cryptococcosis* ; Humans ; Infliximab

No abstract available.
Arthritis, Psoriatic* ; Cryptococcosis* ; Humans ; Infliximab

Arthritis, Psoriatic ; Autoantibodies ; Humans ; Psoriasis

A psoriatic patient may have rheumatoid arthritis, psoriatic arthritis(or both), osteoarthritis or gout. In so far as possible, each of these must be distinguished on clinical grounds with some help from laboratory tests. Psoriatic arthritis is very similar to rheumatoid arthritis but clinically, it is regarded as a unique disease entity, which is found in 1% to 32% of psoriatic individuals. We herein report two cases of psoriatic arthritis that are thought to be distal type and arthritis mutilans on the basis of clinical, serological and radiological features.
Arthritis ; Arthritis, Psoriatic* ; Arthritis, Rheumatoid ; Gout ; Humans ; Osteoarthritis ; Psoriasis

Glucosamine hydrochlorid (Glu-1) used in treatment for arthritis. This study designed to identify anti-inflammatory activities on experimental rats with knee arthritis by formaldehyde and follow by measurement joint's size of animals treated with glucosamine hydrochlorid (Glu-1). The results showed that Glu-1 can reduce knee arthritis by 9.35-9.59% in comparison with reduction (18.56-18.81%) by glutine which used popular in the market. So Glu-1 have less effective than standard glutine (Glu-2). The study identified LD50 by injectable glucosamine hydrochlorid is 6.700.71 g/kg
Glucosamine ; Arthritis, Psoriatic ; Anti-Inflammatory Agents

OBJECTIVE: To explore the difference in phenotype recognition of PsA patients in two clinical scenarios, physical examination with and without ultrasound assessment. METHODS: PsA patients who visited the rheumatology and clinical immunology department of Peking University First Hospital between January 2010 and October 2020, with complete data of clinical and ultrasound assessment were enrolled. The phenotypes were first identified based on physical examination only, and then combined with enthesitis and dactylitis shown on power doppler and gray-scale ultrasound. The phenotype groupings without and with ultrasound assessment were presented with Wayne diagram. The distributions of different clinical phenotypes were compared by using χ² test or Fisher's exact test. The differences of clinical phenotypes with and without ultrasound assessment were compared by using Wilcoxon signed rank test. RESULTS: A total of 227 patients with PsA were enrolled with one or more clinical domains. Physical examination revealed that psoriasis was in 209 (92.1%, 209/227) patients, nail involvement in 98 (43.2%, 98/227) patients, peripheral arthritis in 219 (96.5%, 219/227) patients, axial involvement in 25 (11.0%, 25/227) patients, dactylitis in 80 (35.2%, 80/227) patients, and enthesitis in 18 (7.9%, 18/227) patients. Besides 18 patients with clinical enthesitis, ultrasound scan revealed acute enthesitis in 80 patients, with hypoechogenicity (55 cases), tendon thickening (62 cases), and presence of Doppler signals (48 cases). Similarly, dactylitis on ultrasound was found in 18 patients besides those patients with clinical dactylitis. Compared with the phenotypes recognized based on physical examination only, the additional ultrasound assessment revealed that the most common phenotypes, peripheral arthritis was significantly less frequently recognized (49.8% vs. 27.8%, P < 0.001), however on the other hand, the proportion of the patients with peripheral arthritis and enthesitis was significantly increased (4.4% vs. 18.1%, P < 0.001). The phenotype of peripheral arthritis combined with enthesitis, and dactylitis was also dramatically increased (1.8% vs. 17.6%, P < 0.001). CONCLUSION Ultrasound is a useful tool to identify enthesitis and dactylitis. With the aid of ultrasound assessment, rheumatologists can better identify the lesions of PsA, accurately identify the phenotypes, and further guide the subsequent treatment.
Arthritis, Psoriatic/diagnostic imaging* ; Humans ; Phenotype

The frequency of HLA-B27 antigen in 24 patients with psoriasis vulgaris and 11 patients with psoriatic arthritis were examined using the standard micro-lympho- cytotoxicity technique. There was a high frequency of HLA-B27 in psoriatic spondylitis with or without peripheral arthritis (83.3%) compared to controls (4.7%) and the relative risk of HLA-B27 for developing psoriatic spondylitis was 82.5% which indicates a strong association between HLA-B27 and psoriatic spondylitis in Korean populations. However, there was no stastical significance observed in the groups of patients with peripheral arthritis alone or psoriasis vulgaris in regard to the frequency of HLA-B27.
Arthritis ; Arthritis, Psoriatic ; HLA-B27 Antigen ; Humans ; Psoriasis* ; Spondylitis

Interleukin (IL)-36 is a family of cytokines that belongs to the larger IL-1 superfamily. IL-36 agonist/antagonist binds to the interleukin-36 receptor involving in physiological inflammation regulation and pathogenesis of many inflammatory diseases. In inflammatory joint diseases, the expression of IL-36 changes, and some studies have initially explored the role of IL-36 in these diseases. In psoriatic arthritis, IL-36 signal mediates plasma cell and fibroblast-like synoviocyte crosstalk presenting IL-36 agonist/antagonist imbalance. In rheumatoid arthritis, IL-36 agonists induce fibroblast-like synoviocyte to produce pro-inflammatory factors, while IL-36 antagonist deficiency leads to lesion progression. In osteoarthritis, IL-36 agonists induce chondrocytes to produce catabolic enzymes and pro-inflammatory factors. This article reviews the expression and function of IL-36 in different inflammatory joint diseases to provide a reference for revealing their pathogenic mechanisms and discovering therapeutic targets.
Humans ; Interleukins ; Arthritis, Rheumatoid ; Osteoarthritis/pathology* ; Arthritis, Psoriatic/metabolism* ; Cytokines